Table 3 Summary of regimens in 63 patients of first-line therapies

Combined treatment

XELIRI

2

FOLFIRI

1

XELIRI

1

CPT-11

2

FOLFOXIRI

2

FOLFOX

1

FOLFOXIRI

2

S1

1

FOLFOX

2

XELOX

8

FOLFOX

3

XELOX

23

XELOXIRI

2

Tomudex

1

XELOXIRI

1

CPT-11 + S1

1

L-OHP + FT207

1

Mutant

chemotherapy alone

N = 3

Plus Bev

N = 4

Plus CET

N = 1

Plus T-mab

N = 1

Combined treatment

FOLFIRI

1

XELOX

4

CPT-11+ S1 + vemurafenib

1

XELOXIRI + pertuzumab

1

FOLFOX

2